3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Breast Neoplasms
987
Neoplasms
796
Carcinoma, Non-Small-Cell Lung
763
Prostatic Neoplasms
588
Colorectal Neoplasms
484
Lung Neoplasms
468
Neoplasm Metastasis
413
Multiple Myeloma
382
Leukemia, Myeloid, Acute
377
Ovarian Neoplasms
316
Pancreatic Neoplasms
297
Melanoma
278
Squamous Cell Carcinoma of Head and Neck
258
Recurrence
244
Carcinoma, Hepatocellular
240
Brain Neoplasms
226
Glioblastoma
217
Triple Negative Breast Neoplasms
204
Carcinoma, Renal Cell
200
Head and Neck Neoplasms
198
Lymphoma
193
Stomach Neoplasms
190
Precursor Cell Lymphoblastic Leukemia-Lymphoma
189
Sarcoma
172
Glioma
171
Uterine Cervical Neoplasms
169
Lymphoma, Non-Hodgkin
169
Endometrial Neoplasms
169
Lymphoma, Large B-Cell, Diffuse
166
Urinary Bladder Neoplasms
160
Interventions
darolutamide
2
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Biochemically Recurrent Prostate Cancer
×
90 days
×
Clear all
NCT05794906
2026-05-19
ARASTEP
Bayer
Phase 3
Active not recruiting
985 enrolled
NCT05526248
2026-03-11
ARAMON
Bayer
Phase 2
Completed
28 enrolled
14 charts